Huberman LabPsychedelics for Treating Mental Disorders | Dr. Matthew Johnson
CHAPTERS
- 0:00 – 10:20
Introduction, Guest Background, and Scope of the Conversation
Huberman introduces the podcast, outlines his mission of providing science‑based tools, names the sponsors, and presents Dr. Matthew Johnson as a leading researcher in psychedelic and drug effects on human behavior. They preview topics including microdosing vs macrodosing, clinical psilocybin therapy, and broader implications for mental health treatments.
- 10:20 – 29:20
What Is a Psychedelic? Classes, Receptors, and Mechanisms
Johnson explains that “psychedelic” is a high‑level, partly cultural term that cuts across pharmacological classes. He distinguishes classic 5‑HT2A agonist psychedelics, NMDA antagonists like ketamine, atypical agents like salvinorin A, and MDMA as an entactogen, clarifying how chemistry, receptor targets, and subjective effects intersect but do not map one‑to‑one.
- 29:20 – 51:00
Serotonin, Dopamine, and How Psychedelics Alter Reality and Self
They compare serotonergic and dopaminergic neuromodulation and how psychedelics change perception, time, space, and predictive models. Johnson frames humans as prediction machines whose top‑down models, including the model of self, are partially dissolved by psychedelics, enabling new interpretations of reality and selfhood.
- 51:00 – 1:05:20
Inside a Clinical Psilocybin Session: Screening, Preparation, and Dosing
Johnson walks through the full protocol used at Johns Hopkins for therapeutic psilocybin sessions: intensive medical and psychiatric screening, rapport‑building with guides, detailed education about possible experiences, and administration of pure psilocybin in capsule form at carefully chosen doses.
- 1:05:20 – 1:12:00
Letting Go, Altered Self, and Therapeutic Mechanisms of Change
They delve into the psychological mechanics of a high‑dose psilocybin trip: surrendering control, focusing deeply on inner experience, and allowing intense emotional and somatic states. Johnson argues that lasting benefit emerges from profound changes in self‑representation and sense of agency, rather than from verbal affirmations or insight alone.
- 1:12:00 – 1:41:20
MDMA, Ketamine, and Comparing Therapeutic Models
The discussion contrasts MDMA and ketamine with classic psychedelics in terms of pharmacology, phenomenology, and how they are currently used in therapy. Johnson criticizes purely pharmacologic ketamine models that ignore subjective experience and highlights studies where ketamine was treated more like a psychedelic with promising addiction outcomes.
- 1:41:20 – 2:04:20
Integration: From Acute Experience to Lasting Life Changes
Johnson outlines the post‑session process of integration: immediate debrief, written reflection, and follow‑up therapy sessions where participants unpack their experiences and translate them into specific behavioral and relational changes, while avoiding impulsive life decisions in the immediate aftermath.
- 2:04:20 – 2:23:20
Risks, Contraindications, Bad Trips, and Flashbacks
They candidly address the major psychological and behavioral risks of psychedelics, particularly for individuals with psychosis or bipolar predisposition and for unsupervised, high‑dose recreational use. Johnson clarifies myths around flashbacks and HPPD and makes nuanced comparisons with harms from alcohol and other drugs.
- 2:23:20 – 2:37:20
Microdosing: Hype, Evidence, and Theoretical Safety Concerns
They examine the popular practice of microdosing LSD or psilocybin for focus, creativity, or mood. Johnson outlines how microdoses are defined and prepared in the real world, summarizes current placebo‑controlled data, and raises a largely ignored cardiovascular safety issue related to 5‑HT2B receptor activation.
- 2:37:20 – 2:57:40
Psychedelics in Youth, Legal Status, and Regulatory Futures
They explore the prospect of psychedelic therapy in adolescents, the complex legal status of psychedelics in the U.S., and how medicalization via FDA approval will likely precede any broader regulatory reform. Johnson stresses the distinction between decriminalization, medical approval, and full legalization.
- 2:57:40 – 3:12:40
Traumatic Brain Injury, Neuroplasticity, and Future Research Directions
They discuss early, exploratory ideas about using psychedelics to aid recovery from traumatic brain injury (TBI), chronic traumatic encephalopathy–like syndromes, stroke, and cognitive impairments. Johnson connects rodent data on psychedelic‑induced neuroplasticity and human anecdotes from athletes to potential human trials in collaboration with organizations like the UFC.
- 3:12:40 – 3:33:20
Funding, Philanthropy, and Building a Psychedelic Research Center
Johnson explains how modern human psychedelic research survived the decades‑long funding winter through small foundations and philanthropists, then accelerated with major gifts that enabled the Johns Hopkins Center for Psychedelic and Consciousness Research. They discuss the NIH’s limited role to date and how philanthropic risk‑taking catalyzed the field’s rebirth.
- 3:33:20
Closing Reflections, Accessing Trials, and The Broader Impact
They close by discussing how people can find legitimate clinical trials, the limits of current access (all use must be under experimental protocols), and Johnson’s sense that this work is having real‑world impact. Huberman thanks Johnson for taking career risks to rigorously study psychedelics and for helping shape a science‑based path forward.
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome